Omega-3 and omega-6 fatty acids: Roles in cardiometabolic disease

William Harris

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Omega-3 and omega-6 FAs both have beneficial roles to play in reducing risk for cardiovascular disease (CVD). Although this is largely noncontroversial for the former FA family, some researchers have cautioned that the latter family may actually increase risk for CVD. This review will summarize the relevant human evidence, which shows that, in fact, both FA families are protective. The presumed “pro-inflammatory” nature of the omega-6 FAs (which is the basis for their hypothetical adverse effects) is not supported in a wide variety of human observational and interventional studies. The individual members of the omega-6 FA family can have completely opposing associations with risk; therefore there is no rational basis for summing all of the omega-6 FAs into a single metric and ascribing some health effect to the whole group. The primary omega-6 FA in the diet, linoleic acid, is associated with lower risk for both coronary heart disease and type 2 diabetes, hence lowering intakes (and thus blood levels) would be expected to raise, not lower, risk. Recommended intakes of linoleic acid in the 5%-10% range still apply. Most studies support the view that replacing saturated and trans fats in the diet with both the omega-6 and omega-3 FAs is the best overall strategy for reducing cardiometabolic risk.

Original languageEnglish (US)
Title of host publicationNutrition and Cardiometabolic Health
PublisherCRC Press
Pages193-208
Number of pages16
ISBN (Electronic)9781498704274
ISBN (Print)9781498704267
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Omega-6 Fatty Acids
Linoleic Acid
Cardiovascular Diseases
Diet
Type 2 Diabetes Mellitus
Observational Studies
Coronary Disease
Fats
Research Personnel
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Harris, W. (2017). Omega-3 and omega-6 fatty acids: Roles in cardiometabolic disease. In Nutrition and Cardiometabolic Health (pp. 193-208). CRC Press. https://doi.org/10.1201/9781315119410

Omega-3 and omega-6 fatty acids : Roles in cardiometabolic disease. / Harris, William.

Nutrition and Cardiometabolic Health. CRC Press, 2017. p. 193-208.

Research output: Chapter in Book/Report/Conference proceedingChapter

Harris, W 2017, Omega-3 and omega-6 fatty acids: Roles in cardiometabolic disease. in Nutrition and Cardiometabolic Health. CRC Press, pp. 193-208. https://doi.org/10.1201/9781315119410
Harris W. Omega-3 and omega-6 fatty acids: Roles in cardiometabolic disease. In Nutrition and Cardiometabolic Health. CRC Press. 2017. p. 193-208 https://doi.org/10.1201/9781315119410
Harris, William. / Omega-3 and omega-6 fatty acids : Roles in cardiometabolic disease. Nutrition and Cardiometabolic Health. CRC Press, 2017. pp. 193-208
@inbook{1ec1e567a9be45e8bc5bb033834b3f0d,
title = "Omega-3 and omega-6 fatty acids: Roles in cardiometabolic disease",
abstract = "Omega-3 and omega-6 FAs both have beneficial roles to play in reducing risk for cardiovascular disease (CVD). Although this is largely noncontroversial for the former FA family, some researchers have cautioned that the latter family may actually increase risk for CVD. This review will summarize the relevant human evidence, which shows that, in fact, both FA families are protective. The presumed “pro-inflammatory” nature of the omega-6 FAs (which is the basis for their hypothetical adverse effects) is not supported in a wide variety of human observational and interventional studies. The individual members of the omega-6 FA family can have completely opposing associations with risk; therefore there is no rational basis for summing all of the omega-6 FAs into a single metric and ascribing some health effect to the whole group. The primary omega-6 FA in the diet, linoleic acid, is associated with lower risk for both coronary heart disease and type 2 diabetes, hence lowering intakes (and thus blood levels) would be expected to raise, not lower, risk. Recommended intakes of linoleic acid in the 5{\%}-10{\%} range still apply. Most studies support the view that replacing saturated and trans fats in the diet with both the omega-6 and omega-3 FAs is the best overall strategy for reducing cardiometabolic risk.",
author = "William Harris",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/9781315119410",
language = "English (US)",
isbn = "9781498704267",
pages = "193--208",
booktitle = "Nutrition and Cardiometabolic Health",
publisher = "CRC Press",

}

TY - CHAP

T1 - Omega-3 and omega-6 fatty acids

T2 - Roles in cardiometabolic disease

AU - Harris, William

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Omega-3 and omega-6 FAs both have beneficial roles to play in reducing risk for cardiovascular disease (CVD). Although this is largely noncontroversial for the former FA family, some researchers have cautioned that the latter family may actually increase risk for CVD. This review will summarize the relevant human evidence, which shows that, in fact, both FA families are protective. The presumed “pro-inflammatory” nature of the omega-6 FAs (which is the basis for their hypothetical adverse effects) is not supported in a wide variety of human observational and interventional studies. The individual members of the omega-6 FA family can have completely opposing associations with risk; therefore there is no rational basis for summing all of the omega-6 FAs into a single metric and ascribing some health effect to the whole group. The primary omega-6 FA in the diet, linoleic acid, is associated with lower risk for both coronary heart disease and type 2 diabetes, hence lowering intakes (and thus blood levels) would be expected to raise, not lower, risk. Recommended intakes of linoleic acid in the 5%-10% range still apply. Most studies support the view that replacing saturated and trans fats in the diet with both the omega-6 and omega-3 FAs is the best overall strategy for reducing cardiometabolic risk.

AB - Omega-3 and omega-6 FAs both have beneficial roles to play in reducing risk for cardiovascular disease (CVD). Although this is largely noncontroversial for the former FA family, some researchers have cautioned that the latter family may actually increase risk for CVD. This review will summarize the relevant human evidence, which shows that, in fact, both FA families are protective. The presumed “pro-inflammatory” nature of the omega-6 FAs (which is the basis for their hypothetical adverse effects) is not supported in a wide variety of human observational and interventional studies. The individual members of the omega-6 FA family can have completely opposing associations with risk; therefore there is no rational basis for summing all of the omega-6 FAs into a single metric and ascribing some health effect to the whole group. The primary omega-6 FA in the diet, linoleic acid, is associated with lower risk for both coronary heart disease and type 2 diabetes, hence lowering intakes (and thus blood levels) would be expected to raise, not lower, risk. Recommended intakes of linoleic acid in the 5%-10% range still apply. Most studies support the view that replacing saturated and trans fats in the diet with both the omega-6 and omega-3 FAs is the best overall strategy for reducing cardiometabolic risk.

UR - http://www.scopus.com/inward/record.url?scp=85053557530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053557530&partnerID=8YFLogxK

U2 - 10.1201/9781315119410

DO - 10.1201/9781315119410

M3 - Chapter

AN - SCOPUS:85053557530

SN - 9781498704267

SP - 193

EP - 208

BT - Nutrition and Cardiometabolic Health

PB - CRC Press

ER -